Alnylam outlines goals
Alnylam Pharmaceuticals Inc., a Cambridge company focused on developing drugs through RNAi gene-silencing technology, unveiled a goal to have five drug candidates in the late stages of clinical development by 2015.
In a press release outlining its "Alnylam 5x15" product strategy, the company described the drug candidates as potential treatments for genetically defined diseases.
The release included a statement from Patricia Allen, vice president of finance and treasurer of Alnylam
"Alnylam continues to maintain strong financial performance and discipline, allowing us to increase our 2010 year-end cash guidance to greater than $345 million," Allen said. "In addition, we believe we will finish 2011 with greater than $275 million in cash, excluding any significant new business development partnerships we may form. This financial profile provides us with a multi-year runway to execute on our pipeline goals, with a particular focus on 'Alnylam 5x15' programs."
Alnylam added that it is looking to form new alliances with drug partners. Alnylam has existing partnerships with Takeda and Novartis.